//www.uzleuven-kuleuven.be/lki/trace/sites/default/files/page_headers/header_trace5_3.png

Overview

Before entering clinical development, agents are usually tested against high-passage commercially obtained cell lines and xenografts established from these lines. Although they are very well annotated, the limitations of this current available and conventional preclinical models is their poor predictive value with regard to the clinical response. This is mainly due to the not completely understood adaptations in biologic behavior of cancer cells after long-term growth outside the original human host. In contrary, PDXs maintain the histologic, biologic, genetic and pharmacologic features of their human donor tumor. PDX models are established from the immediate transfer of fresh tumor tissue from patients into immune compromised mice and transplantation in successive generations of mice. As a consequence of this unique human-like characteristics, PDX models have shown to be highly predictive of clinical outcomes and are being used for preclinical drug screening, biomarker identification, biologic studies and personalized medicine strategies. They are a key step in the current oncology R&D pipeline.



Click here for an overview of current PDX models

 

PDX models are established from the immediate transfer of fresh tumor tissue from patients into immune compromised mice and transplantation in successive generations of mice.

Trace PDX models

Search in our online database to find a relevant model that fits into your research pipeline. For more advice, contact us